Impact of GUCY1A3 Gene Variation on Heart Events After Bypass Surgery
The Effect of Polymorphism of the GUCY1A3 rs7692387 Gene on Cardiovascular Events After Coronary Artery Bypass Grafting.
This study is trying to see if a specific gene variation affects the risk of heart problems after bypass surgery in patients who take aspirin.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 800 (estimated) |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Sponsor | Novosibirsk Scientific Research Institute for Circulatory Pathology Academic / other |
| Locations | 2 sites (Novosibirsk, Novosibirskaya Oblast' and 1 other locations) |
| Trial ID | NCT06215300 on ClinicalTrials.gov |
What this trial studies
This observational study evaluates how the polymorphism of the GUCY1A3 gene affects the risk of cardiovascular events following coronary artery bypass grafting (CABG). It focuses on the relationship between genetic factors and aspirin resistance, which is known to complicate postoperative recovery. The study aims to identify patients who carry the GUCY1A3 rs7692387 gene variant and assess its impact on thrombotic complications despite aspirin treatment. By understanding this genetic association, the study seeks to improve patient outcomes after CABG.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with stable ischemic heart disease who are scheduled for coronary artery bypass grafting.
Not a fit: Patients requiring anticoagulants, those with thrombocytopenia, or individuals allergic to aspirin may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to personalized treatment strategies that enhance the prevention of cardiovascular complications in patients undergoing CABG.
How similar studies have performed: Other studies have indicated a significant association between genetic polymorphisms and cardiovascular risks, suggesting that this approach may yield valuable insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Stable ischemic disease 2- 4 * CABG Exclusion Criteria: * the need to take any anticoagulants * thrombocytopenia * allergy to aspirin.
Where this trial is running
Novosibirsk, Novosibirskaya Oblast' and 1 other locations
- Novosibirsk research institute of circulation pathology — Novosibirsk, Novosibirskaya Oblast', Russian Federation (Recruiting)
- Aleksey — Novosibirsk, Russian Federation (Recruiting)
Study contacts
- Study coordinator: Aleksey Kurguzov, MD
- Email: aleksey_kurguzov@mail.ru
- Phone: +79137011917
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.